Om oss

Curasight is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and treatment in multiple cancer types, most notably for brain and prostate cancer.